Introduction
Vacuum-assisted closure (VAC) was first reported in 1997 [1, 2] . It aids in secondary wound healing and has become the most common treatment modality for complex wounds. An open-cell foam dressing placed into the wound cavity and applying controlled negative pressure decrease bacterial colonization, tissue edema, and wound tension and increase blood flow. Using these strategies, VAC promotes wound granulation [2, 3] . VAC has been recently used Abbreviations: VAC, vacuum-asssisted closure. * Corresponding author. Tel: +81 6 6972 1181 Fax: +81 6 6981 8005.
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in gastrointestinal surgery field and for open abdominal wounds [4] [5] [6] . It can shorten time for reconstruction. However there are a few reports regarding the use of VAC for open abdominal wounds with enterocutaneous fistula [7, 8] . Exposure to enteric contents results in wound inflammation and infection, with the further effect of protracted wound healing. Therefore the drainage system is the most critical management factor in wounds with enterocutaneous fistula. In addition the patient was treated with bevacizumab which is reported to increase wound healing complications. Herein we report the successful case to be treated by VAC for an open abdominal wound with enterocutaneous fistulae, and the present report is the first successful case of multiple gastrointestinal perforations.
Presentation of case
A 73-year-old man was admitted to our hospital with severe abdominal pain in March 2014. He had a medical history of surgical resection for ascending colon cancer at another hospital in June 2010. The right iliopsoas muscle and right femoral nerve were partially resected as part of the cancer treatment. The final stage was IIIb (T4bN1bM0) according to the UICC TNM classification [9] , and the cancer microscopically remained at the surgical excision site around the right external iliac artery. Therefore, 5-fluorouracilbased chemotherapy, UFT (300 mg/m 2 /day × 28 days/5 weeks) and radiotherapy (50 Gy to the right external iliac artery) were postoperatively administered. In October 2012, there was a clear recurrence of the cancer at the surgical site, and the patient was admitted to the Department of Clinical Oncology at Osaka Medical Center for Cancer and Cardiovascular Diseases. Due to recurrence, several chemotherapies (CapeOX, mFOLFOX6, FOLFIRI) with bevacizumab had been administered according to the guidelines provided by the Japanese Society for Cancer of the Colon and Rectum [10] in the outpatient clinic.
Abdominal computed tomography (CT) revealed perforation of the intestine (Fig. 1) , and an emergency operation was performed. At surgery, perforation of the sigmoid colon was detected; it was sutured and a diverting ileostomy was performed. On POD 8, a new perforation of the small intestine occurred and a second emergency operation was performed. At that time, there were severe adhesions of the small intestine; therefore a suture or resection of the intestine with the perforation could not be performed. To isolate the enteric contents, a drainage tube was positioned in the perforation site, and the abdominal wall was sutured. However, drainage of enteric contents through the drainage tube was not effective, and the abdominal wound reopened 2 days later (POD 10 after the first operation) (Fig. 2) . In general, enteric contents prevent the wound healing, and it was difficult to manage the drainage at this time. Therefore we introduced VAC therapy (VAC; KCI International, San Antonio, TX, USA) to minimize abdominal wound infection by isolating enteric contents as well as to promote wound granulation. VAC therapy was administered using a VAC system. The entire wound surrounding the fistulae was treated with VAC therapy (Fig. 3) . First, the open wound was washed by saline and an atraumatic contact layer, either Mepitel One (Mölnlycke Health Care, Norcross, GA, USA) and GranuFoam (KCI international), was cut to the shape of the abdominal wound, excluding the fistula holes. The intestinal wall, except the perforation sites, was covered with the atraumatic contact layer as bleeding or perforation of the intestine can occur when the intestine directly contacts GranuFoam [11, 12] . Next, GranuFoam was positioned on the atraumatic contact layer. These layers were then covered with a polyurethane drape (VAC drape), and continuous negative pressure was applied (75 mm Hg). Enteric contents were suctioned using a Continuous Suction Unit MERA Sucuum (Senko Medical Instrument Manufacturing CO, Tokyo, Japan) set to 50 mm Hg continuous negative pressure. Although two additional perforations of the small intestine were observed on POD 11 and POD 14, the additional enteric contents were effectively isolated by the VAC system, and it was continued. An ostomy bag was attached to the VAC drape at the most oral perforation site of the intestine, and oral intake started on POD 21 (Fig. 4) . The VAC system was considered effective in promoting the granulation tissue covering both the intestinal wall and wound bed. Three months after the administration of VAC, enteric contents could be separated into an ostomy bag without suction using MERA Sucuum at the most oral perforation site.
Although the wound granulated well over the exposed intestine, the VAC system was still required to anchor the ostomy bag for drainage of enteric contents. In order to directly attach an ostomy The wound was covered with a film and a VAC connecting tube (arrow) was affixed to it. Controlled negative pressure was then applied and another suction tube (arrowhead) was positioned at the most oral perforation site for the suction of enteric contents at a pressure of 50 mmHg.
bag, an operation was performed to cover the granulation tissue with skin. A portion of the skin around the most oral perforation site was then cut and rotated to cover the granulation tissue at POD 102, and the wound contracted (Fig. 5) . Change and replacement of VAC was necessary approximately once a week. At POD 180, the rotated skin around the most oral perforation site healed well and appeared to be "a uniforate stoma," allowing an ostomy bag to be directly attached without the VAC system. The patient was then transferred to another hospital close to his home.
Discussion
A humanized anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, has been reported to be useful for several cancer therapies and also for colorectal cancer therapy [10, 13] . However, gastrointestinal perforation was observed in 0.9% of patients who underwent chemotherapy with bevacizumab for colorectal cancer, and bevacizumab was reported to increase wound healing complications [14, 15] . High dose of bevacizumab (5.0 mg/kg/week) or concurrent use with chemotherapy, such as oxaliplatine, was reported to increase gastrointestinal perforation [14] . In the present case, oxaliplatine was used as part of chemotherapy, and 5.0 mg/kg/week bevacizumab was administered when the perforation occurred. Gastrointestinal perforation is one of the fatal adverse events of bevacizumab [16] [17] [18] . The mortality of gastrointestinal perforation was 21.7% in cancer patients treated with bevacizumab, whereas it was 15.7% without bevacizumab [19] . The mechanism of bowel perforation with bevacizumab is poorly understood, but it increases the risk of arterial thromboembolic events and venous thromboembolism Fig. 3D , and suction pressure of 50 mmHg was continued to drain intestinal contents. [20, 21] . It suggests that bevacizumab damages gastrointestinal vessels, resulting in ischemic perforation of the normal bowel wall. Therefore, an appropriate treatment is necessary on the case. In this case all perforations occurred within 6 weeks following the final administration of bevacizumab; to the best of our knowledge, this is the first report of multiple intestinal perforations related to bevacizumab. Gastrointestinal perforations and open abdomen were life-threatening events; therefore, we controlled the infection and promoted secondary wound healing with VAC.
In a case of open abdomens with enterocutaneous fistulae, extensive wound care such as negative pressure wound therapy is effective, and mortality rates and recovery can be improved by nutritional support [22] . Therefore isolating enteric contents is the most important factor in the prevention of infection and promotion of wound healing. A few studies reported the usefulness of VAC for open abdomens with enterocutaneous fistula, and VAC has not been reported to confer any additional morbidity or risk of new fistula formation [7, 8, 23] . It was reported that VAC therapy with silicone fistula plug and platelet gel, and low intestinal pressure are effective to manage the fistula [24] [25] [26] . In the present case, there were multiple fistulae and we made "a uniforate stoma" at the most oral fistula by suction using MERA Sucuum. Enteric contents were almost entirely isolated, leading to early oral intake for nutritional recovery.
The patient recovered from life-threatening gastrointestinal perforations and open abdomen, which are difficult to manage. VAC and isolation of enteric contents using MERA Sucuum enabled to prevent infection and early oral intake. Therefore, VAC was one of the useful treatments of open abdomen with enterocutaneous fistulae.
Conclusions
VAC is an effective therapy for the management of an open abdominal wound with enterocutaneous fistulae during the treatment of bevacizumab and improves the nutritional status of the patient in addition to providing appropriate wound treatment.
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